The presented cell and molecular analyses provide strong evidence that VPF, a clinically approved therapeutic agent, can efficiently induce cell death in both MYCN-A and MYCN-NA NB subtypes, independently of YAP/TAZ expression. Here, MYCN is linked to neuroblastoma.